Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 9

Explainer

BPC-157 and TB-500: Achilles tendon healing

A 2026 rat study tested BPC-157 and TB-500 after Achilles repair. TB-500 improved tensile strength and collagen scores; combining both added no extra benefit.

3 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

BPC-157 for UC and MS: the evidence

Rodent models show gut-repair effects, but no human trial has published results for UC or MS. Interaction data with azathioprine or teriflunomide is absent.

3 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Rat Achilles study: BPC-157 and TB-500

A 32-rat Achilles repair study found TB-500 improved load to failure and tendon histology at four weeks. BPC-157 did not reach significance.

3 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Expert digest

CJC-1295 Q3 2026: what changed

Q3 2026 update on CJC-1295: new sports-medicine reviews, Topol cancer-risk commentary, WADA detection advances, and the regulatory picture as of August 2026.

3 Aug 2026 · PeptideMethods Editorial Team · 6 min read
Explainer

The first week on ipamorelin and CJC-1295

Two good nights on an ipamorelin and CJC-1295 blend is not a result yet. Here is what the published timelines actually look like.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Ipamorelin + CJC-1295: early effects

Community reports of better sleep within days of starting ipamorelin and CJC-1295 align with GH-axis pharmacology. Here is what the published literature says.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Peptide blood tests before and after

What a before and after blood panel can show around retatrutide, hCG or Semax, what it cannot, and why interpretation belongs with a clinician.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Why you cannot tell which peptide did it

Running BPC-157, TB-500 and tirzepatide together makes every result uninterpretable. Here is why pharmacology treats one variable at a time.

3 Aug 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Peptide stacking: the attribution problem

Running six research peptides at once creates an attribution problem you cannot solve. Here is what the evidence says about polypharmacy risk and safety gaps.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

PT-141 microdosing: what the evidence shows

PT-141 is FDA-approved at 1.75 mg, where nausea runs at 40% in trials. Here is what the evidence says about lower doses.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Retatrutide + GHK-Cu + ipamorelin stack

What the research says about each compound and the key data gaps before combining retatrutide, GHK-Cu, and ipamorelin with CJC-1295 No DAC.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

Semax + Selank subq: together or apart?

A common question in peptide communities: should Semax and Selank be injected at the same time or spaced out? Here is what the pharmacology says.

3 Aug 2026 · PeptideMethods Editorial Team · 5 min read